| 201.16 5.15 (2.63%) | 11-11 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 239.25 | 1-year : | 252.81 |
| Resists | First : | 204.83 | Second : | 216.44 |
| Pivot price | 201.8 |
|||
| Supports | First : | 186.05 | Second : | 154.79 |
| MAs | MA(5) : | 198.38 |
MA(20) : | 202.87 |
| MA(100) : | 191.21 |
MA(250) : | 164.95 |
|
| MACD | MACD : | -0.9 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 31.4 |
D(3) : | 35.8 |
| RSI | RSI(14): 49 |
|||
| 52-week | High : | 216.44 | Low : | 118.02 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ASND ] has closed above bottom band by 45.0%. Bollinger Bands are 28.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 203.29 - 204.43 | 204.43 - 205.47 |
| Low: | 192.03 - 193.5 | 193.5 - 194.85 |
| Close: | 198.99 - 201.16 | 201.16 - 203.15 |
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
Mon, 10 Nov 2025
Are These 4 Biotech Stocks Set to Beat Q3 Earnings Estimates? - sharewise.com
Sat, 08 Nov 2025
The Bull Case For Ascendis Pharma (ASND) Could Change Following New Long-Term Renal Data on TransCon PTH - Yahoo Finance
Fri, 07 Nov 2025
Ascendis Pharma (ASND) Reports Positive Long-Term Findings for T - GuruFocus
Fri, 07 Nov 2025
Ascendis Pharma (NASDAQ: ASND) posts 91% therapy independence, 84% normocalcemia - Stock Titan
Wed, 05 Nov 2025
BofA Hikes Ascendis Pharma Price Target to $216 Affirms Buy Rating - MSN
Wed, 05 Nov 2025
Ascendis Pharma (NASDAQ: ASND) to Host Third Quarter Results Call Nov. 12 at 4:30 p.m. ET - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 61 (M) |
| Shares Float | 60 (M) |
| Held by Insiders | 0.7 (%) |
| Held by Institutions | 110.2 (%) |
| Shares Short | 3,420 (K) |
| Shares Short P.Month | 2,290 (K) |
| EPS | -5.27 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -3.1 |
| Profit Margin | -55.3 % |
| Operating Margin | -33.5 % |
| Return on Assets (ttm) | -17.2 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 339 % |
| Gross Profit (p.s.) | 6.87 |
| Sales Per Share | 8.1 |
| EBITDA (p.s.) | -4.11 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -165 (M) |
| Levered Free Cash Flow | -104 (M) |
| PE Ratio | -38.18 |
| PEG Ratio | 0 |
| Price to Book value | -64.9 |
| Price to Sales | 24.81 |
| Price to Cash Flow | -73.84 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|